Actively Recruiting
Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer
Led by Wenjin Yin · Updated on 2025-11-18
186
Participants Needed
1
Research Sites
209 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective, randomised, controlled, multicentre study to evaluate the efficacy and safety of continuous versus intermittent pyrotinib therapy in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer.
CONDITIONS
Official Title
Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Pathologically confirmed advanced or locally advanced breast cancer not suitable for curative surgery
- HER2-positive status confirmed at least once in either primary or metastatic tumor
- Previously treated with any number of therapies for advanced breast cancer and eligible for pyrotinib treatment as decided by physician
- At least one measurable tumor lesion or bone-only disease (osteolytic or mixed) according to RECIST v1.1
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate organ function
You will not qualify if you...
- Pregnant or breastfeeding women
- Difficulty in taking or absorbing pyrotinib medication
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Shanghai, China, 200127
Actively Recruiting
Research Team
W
Wenjin Yin, M.D.
CONTACT
Y
Yin
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here